G Medical Innovations (ASX:GMV) - CEO, Dr Yacov Geva
CEO, Dr Yacov Geva
Source: Globes – Israel
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Mobile health company G Medical Innovations (GMV) has added a new revenue stream to its Independent Diagnostic Testing Facilities (IDTF) platform
  • This platform is a patient monitoring service which allows hospital staff to keep track of a patient’s vital signs remotely
  • G Medical has today announced that it will offer remote patient monitoring services to patients undergoing transcatheter aortic valve replacement (TAVR) treatment
  • Hospitals can now monitor pre and post TAVR patients through G Medical’s AECG Patch technology and mobile cardiac telemetry (MCT) device
  • G Medical is steady on the market and shares are currently trading for 4.2 cents each

Mobile health company G Medical Innovations (GMV) has added a new revenue stream to its Independent Diagnostic Testing Facilities (IDTF) platform.

This platform is a patient monitoring service which allows hospital staff to keep track of a patient’s vital signs remotely.

G Medical has today announced that it will offer remote patient monitoring services to patients undergoing transcatheter aortic valve replacement (TAVR) treatment.

Hospitals can now monitor pre and post TAVR patients through G Medical’s AECG Patch technology and mobile cardiac telemetry (MCT) device.

Additionally, G Medical will receive reimbursements for the service and the price will vary depending on the length of the monitoring period.

“Providing hospital partners with the ability to monitor patients undergoing TAVR treatment through our IDTF platform is another valuable revenue channel,” CEO Dr Yacov Geva said.

“As the addressable market for telehealth grows, we are very confident IDTF will continue to scale up. We are making excellent headway in the U.S. university hospital market and our large sales team is identifying many more opportunities for growth,” he added.

G Medical is steady on the market and shares are trading for 4.2 cents each at 12:25 pm AEST.

gmv by the numbers
More From The Market Online

Racura Oncology receives positive results in study of RC110 and RC220

Racura Oncology has obtained positive results from a study into RC220, the company’s proprietary formulation of…

TruScreen continues global growth with product registration in Kenya

TruScreen Group has received product registration in the Republic of Kenya, a priority market for cervical…

Artrya expands US commercial momentum with five-year HonorHealth agreement

Atrya has signed a five-year commercial agreement with major Arizona health system HonorHealth and becomes fifth…

EVE Health Group signs Australian compounding agreement for rapidly rising Men’s Health issue

EVE Health Group has signed an agreement with Optimal Pharmacy Plus Stafford aimed at the Australian…